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Abstract No studies have assessed the economic impact of
extrapyramidal symptoms due to atypical antipsychotics in
schizophrenia. To assess healthcare resource use and medical
costs associated with extrapyramidal symptoms in patients
with schizophrenia. A retrospective analysis of Marketscan
Medicaid Multi-State Database (2004–2009) was conducted.
Patients with schizophrenia and newly initiated on an AAP
were included. Patients with and without extrapyramidal
symptoms were matched using propensity-score matching.
Healthcare utilization and costs were assessed in the 12-month
follow-up period using logistic and two-part (gamma)
regression models. Of 4,621 patients, 583 (12.6 %) had
extrapyramidal symptoms. Patients with extrapyramidal
symptoms had significantly more schizophrenia-related and
all-cause hospitalizations and schizophrenia-related emer-
gency room visits, as well as significantly higher schizo-
phrenia-specific and all-cause total healthcare, inpatient, and
prescription drug costs compared to patients without extra-
pyramidal symptoms. Extrapyramidal symptoms in patients
with schizophrenia is associated with increased healthcare
resource utilization and higher medical costs.
Keywords Extrapyramidal symptoms (EPS) 
Schizophrenia  Healthcare utilization costs  Direct
medical costs
Introduction
Schizophrenia is a chronic, debilitating psychiatric disorder
characterized by deficits in thought processes, perceptions,
and emotional responsiveness, affecting approximately
1 % of the United States (US) population (NIMH 2012).
The overall cost of schizophrenia in 2002 in the US was
estimated at $62.7 billion, and included such direct costs
such as inpatient, outpatient, and long-term medical care,
criminal justice costs, and pharmacotherapy costs, as well
as indirect costs derived from the associated decline in
productivity of the patient and caregivers of the patient
(McEvoy 2007).
Antipsychotic (AP) medications have become a corner-
stone in the management of schizophrenia (Pierre 2005).
However, the use of first generation or ‘‘conventional’’ APs
has been hindered by intolerability, particularly extrapyra-
midal symptoms (EPS), which are risk factors for reduced
adherence and persistence to medications (Pierre 2005). The
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development of second generation, or ‘‘atypical’’ antipsy-
chotics (AAPs), with a lower risk for EPS, was expected to
improve medication adherence through improved tolera-
bility, yet AAP medications also have the potential to cause
EPS due to their blockade of nigrostriatal dopamine D2
receptors (Stahl 2003).
A few studies have shown that adverse events (AEs) are
common in the treatment of schizophrenia and that they are
associated with higher direct and indirect medical costs
(Nasrallah 2002). In a recent study of 876 patients with
schizophrenia using AP medications, 86 % reported experi-
encing at least one AE and 58 % were not completely adherent
to their medication, mainly due to AEs (DiBonaventura et al.
2012). The issue of nonadherence is particularly important in
patients with schizophrenia because it has been shown to
increase the likelihood of symptom recurrence and costly
hospitalizations (Weiden et al. 2004; Weiden and Olfson
1995; Gilmer et al. 2004; Eaddy et al. 2005). However, little is
known about the pharmacoeconomic implications specific to
the treatment of emergent EPS in patients with schizophrenia.
The objective of this study was to assess the healthcare
resource use and direct medical costs associated with EPS in a
population of patients with schizophrenia treated with AAPs
and covered by Medicaid insurance from multiple states.
Methods
Data Source
This retrospective claims analysis utilized data from Mar-
ketscan Medicaid Multi-State Database (MDCD) from the
period of January 1, 2004 to December 31, 2009. The
Medicaid database contains the pooled healthcare experi-
ence of approximately 7 million Medicaid enrollees from
multiple states. It includes inpatient services and prescription
drug claims, as well as information on enrollment, long-term
care, and other medical care. In addition to standard demo-
graphic variables such as age and gender, the database
includes variables of particular value to researchers inves-
tigating Medicaid populations, such as ethnicity, mainte-
nance assistance status, and Medicare eligibility (Thomson
Reuters 2012). Because all study data were accessed using
techniques compliant with the Health Insurance Portability
and Accountability Act (HIPPA) of 1996, and no identifiable
or protected health information was extracted during the
course of the study, the study did not require informed con-
sent or institutional review board (IRB) approval.
Sample Selection and Patient Population
Patients who filled a prescription for AAPs between July 1,
2004 and December 31, 2008 were selected and the date of
the first AAP prescription fill was defined as the index date.
Patients were eligible if they were aged 18–64 years and
were continuously enrolled in medical and pharmacy
benefits in the baseline (6 months prior to the index date)
and follow-up period (12 months post the index date).
Patients were excluded if they were dually eligible for
Medicaid and Medicare benefits (Fig. 1). At least one
diagnosis of schizophrenia was required in the baseline
period to ensure that EPS developed after the diagnosis of
schizophrenia. A schizophrenia diagnosis was defined as
C1 inpatient primary schizophrenia diagnosis (ICD-9 code
295.x) or C1 outpatient schizophrenia diagnosis in the
baseline period and C2 outpatient schizophrenia diagnoses
in the baseline and follow-up periods. Patients were
excluded if they filled a prescription for AAPs in the
baseline period, or a prescription for an AP in the study
period. Patients with a diagnosis of EPS or who received
medication used in the management of EPS (i.e., benztro-
pine, trihexyphenidyl, amantadine, biperiden) in the
6 months prior to the index date were also excluded. Other
exclusion criteria included patients who had the first EPS
occurrence more than 90 days after the index date and
those with a diagnosis code for Parkinson’s disease during
the study period.
Patient Demographics and Clinical Characteristics
Patients were classified as having EPS if they had either an
ICD-9 code for EPS (333.1, 333.2, 333.3, 333.72, 333.85,
333.90, 333.92, 333.99, 781.0, 332.1) or a prescription
claim for a medication to treat EPS (benztropine, trihexy-
phenidyl, amantadine, biperiden) during the 90 days post-
index date. Age, gender, and race were captured from the
enrollment data. Year of index date and index AAP treat-
ment was defined on the index date. Baseline resource
utilization (medication burden defined as the number of
distinct therapeutic classes, all-cause hospitalizations, all-
cause emergency room (ER) and office visits, comorbidi-
ties, and Charlson Comorbidity Index (CCI) (Deyo et al.
1992) were defined in the 6 months prior to the index date.
Outcome Measures
The study outcomes included all-cause and schizophrenia-
related healthcare resource utilization and costs. Hospital-
izations, ER and outpatient visits, as well as associated
healthcare costs were assessed in the 12-month follow-up
period. Cost outcomes were computed as the combined health
plan and patient paid amounts, including total healthcare,
outpatient, hospitalizations, ER and office visits, and outpa-
tient prescription costs. Schizophrenia-related utilization and
costs were defined as those services with an ICD-9 diagnosis
of schizophrenia (295.xx, primary diagnosis for inpatient
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service, and any diagnoses for outpatient services). Schizo-
phrenia-related pharmacy utilization and costs included
outpatient prescription drug costs for psychotropic medica-
tions, including AAPs and antidepressants, anxiety medica-
tions, and medications for mood stabilizers.
Statistical Analysis
Patients with EPS were matched in a 1:1 ratio to those
without EPS using a propensity score method. Propensity
score matching is a commonly used and widely accepted
method to control for observed differences between patient
cohorts, enabling a more robust comparison of the outcomes
between cohorts (Austin 2009). Logistic regression was used
to generate propensity scores, with the model variables of
age, gender, race/ethnicity, index year, index treatment, CCI,
medication burden, all-cause hospitalizations, ER and office
visits, anxiety, personality and substance abuse disorders,
major depression, bipolar disorder, hypertension, and met-
abolic syndrome in the baseline period (Austin 2009). For
matching, the nearest neighbor method was used. Descrip-
tive statistics for both groups before and after matching was
used to verify that the baseline characteristics were com-
parable (for continuous variables used t tests, and categorical
variables used Pearson Chi-square tests). The absolute
standardized differences comparing baseline covariates
between patients with EPS and those without in the unmat-
ched and matched samples were reported. Unlike t tests and
other statistical analyses, the standardized difference, which
compares the mean difference in units of the pooled standard
AAPs during 7/1/2004 and 12/31/2008 (First AAPS as the index date)a
(N=571,896)
Age 18 to 64 years in the baseline and follow-up periodb,c
(n=344,787)
Not dually eligible for Medicaid and Medicare benefits in the 
baseline and follow-up periodsb,c (n=239,696)
Continuously enrolled in medical and pharmacy benefits in the 
baseline and follow-up periodsb,c (n=135,428)
≥1 inpatient primary schizophrenia diagnosis 
OR 
≥1 schizophrenia diagnosis in the baseline period and ≥2 schizophrenia diagnoses in the 
baseline and follow-up periodsb,c
(n=23,023)
Exclude patients with AAPs in the baseline periodb (n=7,935)
Exclude patients with APs in the baseline and follow-up periodb,c 
(n=5,119)
Exclude patients with EPS diagnosis in the baseline perioda (n=5,064)
Exclude patients with EPS medicationsd in the baseline 
perioda,(n=4,900)
Exclude patients with Parkinson’s diseasee in the baseline and follow-up 
periodb,c (n=4,891)
Exclude patients with first EPS occurrence after 90 days post the index 
date,(n=4,621)
Fig. 1 Flow chart of sample
selection. aExcluded patients with
[1 AAP treatment at the same
date. bBaseline period: 6 months
prior to the index date. cFollow-up
period: 12 months post index date.
dIncluding benztropine,
trihexyphenidyl, biperiden,
amantadine. eICD-9 code 332.0 for
Parkinsonism or Parkinson’s
disease and 331.82 for dementia
with Parkinsonism. AAP atypical
antipsychotics, EPS
extrapyramidal symptoms
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deviation, is not influenced by sample size (Austin 2009).
After matching, logistic regression modeling was conducted
to compare healthcare utilization (any all-cause or schizo-
phrenia-specific hospitalization, ER, and office visit), and
linear gamma regression modeling or two-part models were
conducted to compare cost outcomes between the two groups
depending on the distribution of the cost outcomes In these
two-part models, the first part accounted for the probability
of nonzero costs using logistic regression, and the second
part was for the cost level, conditional on nonzero costs using
linear gamma regression with log link. Also reported for the
cost models were the marginal effects in terms of dollars and
bootstrapping 95 % confidence intervals (CIs). Analyses
were conducted using SAS version 9.2 (SAS Institute, Inc.,
Cary, North Carolina, US). Sensitivity analyses were con-
ducted to compare the healthcare utilization and costs in
the 6 months post the index date, using the same statistical
methods as described above.
Results
Patient Population
Between July 1, 2004 and December 31, 2008, a total of
571,896 patients were identified using an AAP (Fig. 1). After
inclusion and exclusion criteria were applied, the total sample
size was 4,621 patients; of whom, 583 (12.6 %) had EPS.
Table 1 summarizes the baseline demographic and clinical
information, before matching. The EPS group was younger,
with a greater proportion of males, African Americans, and
risperidone use as index treatment (P \ 0.001, all cases,
Table 1). After matching, there were no significant between-
group differences on baseline covariates and all absolute
standard differences were less than 0.1 (data not shown).
Healthcare Utilization and Costs
Table 2 represents the unadjusted healthcare utilization and
costs results during the 12-month follow-up period before
propensity matching. Higher all-cause and schizophrenia-
specific hospitalizations were observed in patients with EPS
compared with those without EPS (odds ratio [OR] = 1.53,
95 %CI = 1.28–1.84, and OR = 2.16, 95 % CI = 1.73–2.70,
respectively, P \ 0.001). Additionally, patients with EPS
compared with those without EPS were 1.68 times more
likely to have schizophrenia-specific ER visits (OR = 1.68,
95 % CI = 1.38–2.04, P \ 0.001). Similarly, higher all-
cause prescription costs (P = 0.035), schizophrenia-specific
ER, inpatient, prescription drug, and total healthcare costs
(P \ 0.001), and schizophrenia-specific outpatient costs
(P = 0.004) in the 12-month follow-up period were also
found in the EPS group (Table 2).
Multivariate Analysis
Patients with EPS had a higher likelihood of schizophrenia-
related (OR = 1.56, 95 % CI = 1.15–2.11, P = 0.004) and
all-cause hospitalizations (OR = 1.33, 95 % CI = 1.04–
1.70, P = 0.022), and a higher likelihood of schizophrenia-
related ER visits (OR = 1.30, 95 % CI = 1.00–1.69,
P = 0.05), compared with patients without EPS (Table 3).
Adjusted all-cause total healthcare, inpatient, and pre-
scription drug costs were higher for patients with EPS
compared with those without EPS. Differences in costs
between patients with and without EPS were noted in all-
cause total healthcare ($3,552 [95 % CI = $683–$5,830]),
all-cause inpatient ($2,140 [95 % CI = $508–$4,019]),
and all-cause prescription drug ($965 [95 % CI = $511–
$1,516]) costs (Table 3).
Adjusted schizophrenia-specific total healthcare, inpa-
tient, ER, and prescription drug costs were greater in patients
with EPS compared with those without EPS, with differences
in costs observed in schizophrenia-specific total healthcare
($2,689 [95 % CI = $1,518–$4,190]); schizophrenia-spe-
cific inpatient ($1,307 [95 % CI = $477–$2,346]); schizo-
phrenia-specific ER ($103 [95 % CI = $50–$163)]; and
schizophrenia-specific prescription drug ($884 [95 %
CI = $504–$1,283]) costs (Table 3).
Sensitivity Analysis
A sensitivity analysis assessed healthcare resource use and
costs during the first 6 months after the index date. Results
were consistent with the original 12-month results. In the
matched population, patients with EPS were more likely to be
hospitalized than those without EPS (all-cause OR = 1.50
(95 % CI = 1.13, 1.97], P = 0.004); schizophrenia-specific
OR = 1.83 [95 % CI = 1.26, 2.66], P = 0.001). The
likelihood of schizophrenia-specific ER visits was also
increased in those with EPS versus those without EPS
(OR = 1.48, [95 % CI = 1.10, 1.99], P = 0.009).
Patients with EPS had higher all-cause and schizophre-
nia-specific costs: all-cause ER ($207 difference, 95 % CI
$76, $397), all-cause inpatient ($1,659 difference, 95 % CI
$528, $2,956), all-cause total healthcare ($2,846 differ-
ence, 95 % CI $1,339, $4,377), schizophrenia-specific ER
($63 difference, 95 % CI $32, $103), schizophrenia-spe-
cific inpatient ($862 difference, 95 % CI $232, $1,576),
and schizophrenia-specific total healthcare ($1,671 differ-
ence, 95 % CI $1,041, $2,643) costs.
Discussion
This is the first study to empirically demonstrate healthcare
utilization and costs associated with EPS among patients
54 Community Ment Health J (2014) 50:51–58
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with schizophrenia newly treated with AAPs. Despite
treatment with AAPs, incident EPS occurred in approxi-
mately one out of eight patients in our study sample. In this
analysis, both schizophrenia-related and all-cause health-
care utilization and costs were greater in patients with EPS.
Our descriptive observation that the incidence of EPS
Table 1 Comparison of demographic characteristics between EPS and Non EPS unmatched sample (6 months prior to index date)
Variable Unmatched population Absolute standardized differences
EPS Non EPS P value
Patients (n) 583 4,038
Age, mean (SD) 36.5 (12.3) 38.9 (11.9) <0.001 0.002
Sex (n) (%) <0.001
Male 336 (57.6) 1,972 (48.8) 0.177
Female 247 (42.4) 2,066 (51.2) 0.177
Non fee for service health plans (n) (%) 227 (38.9) 1,523 (37.7) 0.570 0.025
Race (n) (%) 0.036
White 178 (30.5) 1,453 (36.0) 0.116
African American 337 (57.8) 2,216 (54.9) 0.059
Hispanic 9 (1.5) 47 (1.2) 0.033
Other 59 (10.1) 322 (8.0) 0.075
Year of the first AAP fill (n) (%) 0.540
2004 135 (23.2) 956 (23.7) 0.012
2005 161 (27.6) 1,230 (30.5) 0.063
2006 102 (17.5) 690 (17.1) 0.011
2007 81 (13.9) 523 (13.0) 0.028
2008 104 (17.8) 639 (15.8) 0.054
Index treatment (n) (%) <0.001
Aripiprazole 40 (6.9) 496 (12.3) 0.185
Clozapine 7 (1.2) 42 (1.0) 0.015
Olanzapine 32 (5.5) 580 (14.4) 0.300
Paliperidone 11 (1.9) 73 (1.8) 0.006
Quetiapine 52 (8.9) 954 (23.6) 0.407
Risperidone 358 (61.4) 1,430 (35.4) 0.539
Ziprasidone 83 (14.2) 463 (11.5) 0.083
Resource utilization
Medication burden, mean (SD) 2.6 (4.0) 3.8 (4.9) <0.001 0.003
All-cause hospitalizations (C1) (n) (%) 238 (40.8) 1,392 (34.5) 0.003 0.131
All-cause ER visits (C1), (n) (%) 357 (61.2) 2,287 (56.6) 0.036 0.094
All-cause office visits (C1), (n) (%) 269 (46.1) 2,123 (52.6) 0.004 0.129
CCI, mean (SD) 0.4 (1.1) 0.5 (1.2) 0.033 0.001
Comorbidities (n) (%)
Anxiety disorders 57 (9.8) 451 (11.2) 0.315 0.046
Major depression 92 (15.8) 636 (15.8) 0.985 0.001
Bipolar disorder 24 (4.1) 134 (3.3) 0.322 0.042
Personality disorders 24 (4.1) 157 (3.9) 0.790 0.012
Substance use disorders 149 (25.6) 979 (24.2) 0.490 0.030
Hypertension 95 (16.3) 802 (19.9) 0.042 0.093
Metabolic syndrome 65 (11.1) 684 (16.9) <0.001 0.167
EPS is defined by EPS symptoms and medications in 90 days post the index date. Continuous variables are reported as mean (SD); P values are
calculated by using 2-sample t test; Dichotomous and categorical variables are reported as N (%); P values are calculated by using Chi-square
test
EPS extrapyramidal symptoms, n amount analyzed from the total population (N), % percentage, SD standard deviation, AAP atypical anti-
psychotics, ER emergency room, CCI Charlson comorbidity index
Community Ment Health J (2014) 50:51–58 55
123
varied among AAPs is consistent with clinical trials dem-
onstrating a higher use of EPS medications in some treat-
ment arms (Miller 2008), However, this study was not
designed to directly assess the cost and health resource
implications of AAPs based on the risk of EPS. Future
studies are warranted to assess the effects of different risks
for EPS among AAPs affects health resource use and costs.
Managing EPS can be challenging, and the most com-
mon intervention is a reduction in dose of the AP medi-
cation (Courey 2007). However, this strategy could result
in subtherapeutic dosing, potentially leading to symptom
worsening or a full exacerbation of symptoms. Symptom-
atic relapse is associated with higher inpatient and outpa-
tient services and medication costs, with costs increasing
with subsequent relapses (Ascher-Svanum et al. 2010). To
manage symptoms, the use of medications, such as anx-
iolytic agents, beta-blockers, anticholinergic, or antipar-
kinsonian agents is often necessary. However, these
medications, all of which are available in generic forms,
are not likely to have contributed to the higher psycho-
tropic medication costs observed in this analysis. A more
plausible explanation is the use of psychotropic polyphar-
macy, which can increase treatment costs in the absence of
clear benefits. Such practices may increase the risk for
metabolic side effects, which may further increase total
treatment costs in the absence of clear efficacy benefits
(Correll et al. 2007; Barnes and Paton 2011). Our study did
not investigate whether or not AP polypharmacy contrib-
uted to medication costs since the largest driver of costs
was hospitalizations.
This study has several limitations. Claims data may not
be fully representative of all patients with the disease.
However, schizophrenia patients in the US are predomi-
nantly insured by Medicaid and the multi-state nature of
this dataset make the study sample generalizable to other
public sector settings in the US. Our use of claims for
Table 2 Unadjusted healthcare utilization and costs for patients with and without EPS unmatched sample (12 months post index date)
Variable EPS Non EPS Odds ratio (95 % CI) P value
Patients (n) 583 4,038
Resource utilization (n) (%)
All-cause hospitalizations (C1) 213 (36.5) 1,102 (27.3) 1.53 (1.28, 1.84) <0.001
All-cause ER visits (C1) 367 (63.0) 2,520 (62.4) 1.02 (0.86, 1.23) 0.800
All-cause office visits (C1) 393 (67.4) 2,854 (70.7) 0.86 (0.71, 1.03) 0.107
Schizophrenia-specific hospitalizations (C1) 121 (20.8) 437 (10.8) 2.16 (1.73, 2.70) <0.001
Schizophrenia-specific ER visits (C1) 169 (29.0) 789 (19.5) 1.68 (1.38, 2.04) <0.001
Schizophrenia-specific office visits (C1) 81 (13.9) 500 (12.4) 1.14 (0.89, 1.47) 0.304
Cost difference (95 % CI)
Healthcare costs, mean (SD)a
All-cause ER costs $1,060 (2,481) $947 (2,336) $112 (-$92, $317) 0.303
All-cause inpatient costs $7,196 (17,608) $6,012 (25,165) $1,184 (-$931, $3,298) 0.154
All-cause outpatient costs $5,734 (9,803) $6,027 (11,481) -$293 (-$1,273, $687) 0.510
All-cause prescription drug costs $4,693 (4,818) $4,228 (5,929) $465 ($33, $897) 0.035
All-cause total healthcare costs $18,682 (24,337) $17,214 (30,891) $1,468 (-$1,150, $4,086) 0.190
Schizophrenia-specific ER costs $232 (604) $130 (482) $102 ($58, $145) <0.001
Schizophrenia-specific inpatient costs $3,146 (9,978) $1,366 (6,294) $1,780 ($1,184, $2,377) <0.001
Schizophrenia-specific outpatient costs $2,494 (5,656) $1,987 (5,558) $507 ($23, $991) 0.040
Schizophrenia-specific prescription drug costs $3,505 (3,580) $2,765 (2,916) $739 ($478, $1,001) <0.001
Atypical antipsychotics $3,202 (3,345) $2,425 (2,699) $777 ($535, $1,019) <0.001
Antidepressants $228 (488) $264 (527) -$36 (-$81, $9) 0.100
Anxiety medications $94 (330) $106 (362) -$13 (-$44, $19) 0.397
Mood stabilizers $57 (325) $51 (344) $5 (-$24, $35) 0.718
Schizophrenia-specific total healthcare costs $9,377 (13,358) $6,249 (9,587) $3,128 ($2,248, $4,009) <0.001
EPS is defined by EPS symptoms and medications in 90 days post the index date. Continuous variables are reported as mean (SD); P values are
calculated by using 2-sample t test; Dichotomous and categorical variables are reported as N (%); P values are calculated by using Chi-square
test
EPS extrapyramidal symptoms, n amount analyzed from the total population (N), % percentage, SD standard deviation, AAP atypical anti-
psychotics, ER emergency room, CCI Charlson comorbidity index
a Standardized; US$
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either EPS or medications frequently used to treat EPS
likely underestimates the true incidence of treatment-rela-
ted EPS, since providers may either not identify such
symptoms or may deem them clinically insignificant. In
addition, we included multiple forms of EPS such as Par-
kinsonism and akathisia in our definition, though there may
be differences in how such EPS affects outcomes. As a
result, our sample may not be representative of all forms of
medication-induced EPS, but rather only the most severe
that led to pharmacological treatment or a supplemental
diagnosis. Moreover, some treatments for EPS such as
diphenhydramine, are available as over-the-counter prep-
arations and would not be identified by our method. Future
studies using linked clinical data will enable researchers to
assess the true incidence and consequences of EPS,
including the effects of EPS of varying severity, duration,
and responsiveness to treatment. This study defined
patients as ‘‘newly initiated’’ on antipsychotic treatment as
those who had not filled an antipsychotic prescription
within 6 months of the index date. However, given the
mean age of the population, it is likely that patients had
previously been exposed to an antipsychotic agent prior to
this period. It is unknown how prior exposure affects the
current manifestation of EPS, and thereby costs. Our
interest was in the acute effects of treatment-emergent acute
EPS, and following a 6-month medication-free period it was
assumed that there would be no carryover of EPS from prior
regimens. Similarly, we did not assess duration of illness
and previous psychotic episodes, all of which may also have
had an effect on the frequency and severity of EPS in the
current time horizon but are not available in claims data.
However, since age was one of the matching variables, it is
Table 3 Adjusted healthcare utilization and costs for patients with and without EPS matched sample (12 months post index date)
Variable EPS Non EPS Odds ratio (95 % CI)a P value
Patients (n) 583 583
Resource utilization (n) (%)a
All-cause hospitalizations (C1) 213 (36.5) 176 (30.2) 1.33 (1.04, 1.70) 0.022
All-cause ER visits (C1) 367 (63.0) 384 (65.9) 0.88 (0.69, 1.12) 0.298
All-cause office visits (C1) 393 (67.4) 363 (62.3) 1.25 (0.99, 1.60) 0.066
Schizophrenia-specific hospitalizations (C1) 121 (20.8) 84 (14.4) 1.56 (1.15, 2.11) 0.004
Schizophrenia-specific ER visits (C1) 169 (29.0) 139 (23.8) 1.30 (1.00, 1.69) 0.046
Schizophrenia-specific office visits (C1) 81 (13.9) 75 (12.9) 1.09 (0.78, 1.53) 0.606
Cost difference (95 % CI)b
Healthcare costs, mean (SD)b
All-cause ER costs $1,060 (111) $912 (104) $148 (-$78, $455)
All-cause inpatient costs $7,196 (756) $5,055 (517) $2,140 ($508, $4,019)
All-cause outpatient costs $5,734 (412) $5,435 (433) $299 (-$965, $1,359)
All-cause prescription drug costs $4,693 (198) $3,728 (170) $965 ($511, $1,516)
All-cause total healthcare costs $18,682 (930) $15,130 (810) $3,552 ($683, $5,830)
Schizophrenia-specific ER costs $232 (25) $128 (16) $103 ($50, $163)
Schizophrenia-specific inpatient costs $3,146 (411) $1,840 (282) $1,307 ($477, $2,346)
Schizophrenia-specific outpatient costs $2,494 (266) $2,100 (221) $395 (-$214, $1,094)
Schizophrenia-specific prescription drug costs $3,505 (143) $2,621 (123) $884 ($504, $1,283)
Atypical antipsychotics $3,202 (136) $2,348 (115) $855 ($521, $1,220)
Antidepressants $228 (21) $209 (19) $20 (-$34, $72)
Anxiety medications $94 (14) $82 (15) $12 (-$28, $45)
Mood stabilizers $57 (13) $51 (13) $6 (-$28, $42)
Schizophrenia-specific total healthcare costs $9,377 (517) $6,688 (441) $2,689 ($1,518, $4,190)
EPS is defined by EPS symptoms and medications in 90 days post the index date
Bootstrapping CIs were provided for the cost differences
EPS extrapyramidal symptoms, n amount analyzed from the total population (N); % percentage; SD standard deviation, CI confidence interval,
US United States, ER emergency room
a Logistic regression model was used to compare healthcare utilization variables and two-part or gamma regression models were used to
healthcare costs without controlling for other covariates (all balanced after propensity score matching)
b Standardized; US$
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likely that the EPS and non-EPS cohorts had similar
durations of illness. Propensity score matching ensured
balance between cohorts on observable patient character-
istics, but unobserved confounding may have contributed
to the outcomes. However, regression modeling controlled
for prior health resource utilization and costs, which were
the primary outcomes of the study. Finally, the medication
cost estimates in this analysis do not take into consideration
discount programs or other rebates.
Conclusions
The presence of EPS in patients with schizophrenia treated
with AAPs is associated with increased all-cause and
schizophrenia-specific healthcare resource utilization and
costs. Risk for EPS varies among AAPs, and these results
serve to remind clinicians that careful treatment selection
and monitoring of patients for EPS is important when
considering alternatives among the available AAPs.
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